SANTHERA PHARMACEUTICALS HOLDING AG Financials Santhera Pharmaceuticals Holding AG OTC Markets
Equities
SPHDF
CH1276028821
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.7 USD | +4.00% |
|
-.--% | -.--% |
| 06-19 | Transcript : Santhera Pharmaceuticals Holding AG - Special Call | |
| 06-18 | Santhera Secures CHF69 Million Financing for Bond Repayment, Cash Runway Extension | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 126 | 53.93 | 55.82 | 75.32 | 90.32 | 76.48 | - | - |
| Enterprise Value (EV) 1 | 94.65 | 112.7 | 55.82 | 75.32 | 90.32 | 76.48 | 76.48 | 76.48 |
| P/E ratio | -6.55 x | -0.55 x | -0.82 x | -1.18 x | - | -2.95 x | -11.1 x | 1.96 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 1.67 x | 3.59 x | -35 x | 10.1 x | 0.87 x | 3.19 x | 1.27 x | 0.57 x |
| EV / Revenue | 1.67 x | 3.59 x | -35 x | 10.1 x | 0.87 x | 3.19 x | 1.27 x | 0.57 x |
| EV / EBITDA | -22.2 x | -1.17 x | -1.41 x | -1.79 x | - | -2.83 x | -25.5 x | 1.27 x |
| EV / FCF | 50.5 x | -1.24 x | -1.49 x | -2.53 x | - | -2.39 x | -12.7 x | 1.25 x |
| FCF Yield | 1.98% | -80.7% | -66.9% | -39.6% | - | -41.8% | -7.84% | 79.8% |
| Price to Book | 5.87 x | - | 34.2 x | -2.13 x | - | - | - | - |
| Nbr of stocks (in thousands) | 1,111 | 1,926 | 4,197 | 5,458 | 9,207 | 9,215 | - | - |
| Reference price 2 | 113.4 | 28.00 | 13.30 | 13.80 | 9.810 | 8.300 | 8.300 | 8.300 |
| Announcement Date | 3/24/20 | 4/29/21 | 6/10/22 | 4/27/23 | 4/25/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 75.38 | 15.01 | -1.595 | 7.473 | 103.4 | 24 | 60 | 135 |
| EBITDA 1 | -5.671 | -45.94 | -39.57 | -42.12 | - | -27 | -3 | 60 |
| EBIT 1 | -10.44 | -53.08 | -56.89 | -51.98 | 68.81 | -30 | -6 | 57 |
| Operating Margin | -13.85% | -353.65% | 3,566.65% | -695.52% | 66.56% | -125% | -10% | 42.22% |
| Earnings before Tax (EBT) 1 | -18.39 | -67.46 | -54.72 | -69.69 | - | -35 | -10 | 58 |
| Net income 1 | -18.97 | -67.66 | -55.53 | -70.15 | - | -35 | -10 | 53 |
| Net margin | -25.17% | -450.82% | 3,481.25% | -938.66% | - | -145.83% | -16.67% | 39.26% |
| EPS 2 | -17.30 | -50.80 | -16.20 | -11.70 | - | -2.810 | -0.7500 | 4.230 |
| Free Cash Flow 1 | 2.497 | -43.54 | -37.36 | -29.8 | - | -32 | -6 | 61 |
| FCF margin | 3.31% | -290.14% | 2,342.38% | -398.73% | - | -133.33% | -10% | 45.19% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 101.67% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 115.09% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/24/20 | 4/29/21 | 6/10/22 | 4/27/23 | 4/25/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|
| Net sales 1 | 5.7 | 10.3 | 13.7 | 21.4 |
| EBITDA | - | - | - | - |
| EBIT | - | - | - | - |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income | - | - | - | - |
| Net margin | - | - | - | - |
| EPS | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | - | - | - | - |
1CHF in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | 58.8 | - | - | - | - | - | - |
| Net Cash position | 31.4 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -1.279 x | - | - | - | - | - | - |
| Free Cash Flow 1 | 2.5 | -43.5 | -37.4 | -29.8 | - | -32 | -6 | 61 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | -71% | -24% | 57% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | 19.30 | - | 0.3900 | -6.490 | - | - | - | - |
| Cash Flow per Share | - | -32.70 | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 3/24/20 | 4/29/21 | 6/10/22 | 4/27/23 | 4/25/24 | - | - | - |
1CHF in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
8.3
CHF
Average target price
34.5
CHF
Spread / Average Target
+315.66%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +4.96% | 70.02B | |
| +16.65% | 9.05B | |
| -22.81% | 4.43B | |
| +14.83% | 4.16B | |
| +19.21% | 3.83B | |
| -1.86% | 2.06B | |
| +8.78% | 2.02B | |
| -36.94% | 1.9B | |
| -45.25% | 1.71B |
- Stock Market
- Equities
- SANN Stock
- SPHDF Stock
- Financials Santhera Pharmaceuticals Holding AG
